JP2007511603A - ４−置換イミダゾール類 - Google Patents

４−置換イミダゾール類 Download PDF

Info

Publication number
JP2007511603A
JP2007511603A JP2006541086A JP2006541086A JP2007511603A JP 2007511603 A JP2007511603 A JP 2007511603A JP 2006541086 A JP2006541086 A JP 2006541086A JP 2006541086 A JP2006541086 A JP 2006541086A JP 2007511603 A JP2007511603 A JP 2007511603A
Authority
JP
Japan
Prior art keywords
disease
compound
hydrogen
disorder
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006541086A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007511603A5 (https=
Inventor
ジェイムズ・エムプフィールド
アイフィーオン・フィリップス
スコット・スロウナー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007511603A publication Critical patent/JP2007511603A/ja
Publication of JP2007511603A5 publication Critical patent/JP2007511603A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006541086A 2003-11-19 2004-11-15 ４−置換イミダゾール類 Pending JP2007511603A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303075A SE0303075D0 (sv) 2003-11-19 2003-11-19 4-substituted imidazoles
PCT/SE2004/001660 WO2005049612A1 (en) 2003-11-19 2004-11-15 4-substituted imidazoles

Publications (2)

Publication Number Publication Date
JP2007511603A true JP2007511603A (ja) 2007-05-10
JP2007511603A5 JP2007511603A5 (https=) 2007-11-22

Family

ID=29729099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541086A Pending JP2007511603A (ja) 2003-11-19 2004-11-15 ４−置換イミダゾール類

Country Status (13)

Country Link
US (1) US7384954B2 (https=)
EP (1) EP1687303A1 (https=)
JP (1) JP2007511603A (https=)
KR (1) KR20060100426A (https=)
CN (1) CN1882584A (https=)
AU (1) AU2004291457A1 (https=)
BR (1) BRPI0416629A (https=)
CA (1) CA2546096A1 (https=)
IL (1) IL175438A0 (https=)
NO (1) NO20062862L (https=)
SE (1) SE0303075D0 (https=)
WO (1) WO2005049612A1 (https=)
ZA (1) ZA200604018B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515754A (ja) * 2011-04-20 2014-07-03 サントル ナスィオナル ド ラ ルシェルシュ スィアンティフィク（セ．エン．エル．エス．） １，４−二置換１，２，３−トリアゾール、その調製方法、ならびにその診断的および治療的使用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0303076D0 (sv) * 2003-11-19 2003-11-19 Astrazeneca Ab 5-substituted imidazoles
WO2006065217A1 (en) * 2004-12-16 2006-06-22 Astrazeneca Ab Nicotinic acetycholine receptor ligands

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01156979A (ja) * 1987-09-10 1989-06-20 Merck Sharp & Dohme Ltd 老人性痴呆症治療用のオキサジアゾリルーアザビシクロヘプタン類
WO2002016355A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
JP2002255965A (ja) * 2000-12-29 2002-09-11 Pfizer Prod Inc Ｃｎｓおよび他の疾患のための医薬組成物
WO2003044020A1 (fr) * 2001-11-23 2003-05-30 Sanofi-Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane, leur preparation et leur application en therapeutique
WO2004043960A1 (en) * 2002-11-11 2004-05-27 Neurosearch A/S 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599916B2 (en) * 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01156979A (ja) * 1987-09-10 1989-06-20 Merck Sharp & Dohme Ltd 老人性痴呆症治療用のオキサジアゾリルーアザビシクロヘプタン類
WO2002016355A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
JP2002255965A (ja) * 2000-12-29 2002-09-11 Pfizer Prod Inc Ｃｎｓおよび他の疾患のための医薬組成物
WO2003044020A1 (fr) * 2001-11-23 2003-05-30 Sanofi-Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo-[3.2.2]nonane, leur preparation et leur application en therapeutique
WO2004043960A1 (en) * 2002-11-11 2004-05-27 Neurosearch A/S 1,4-diazabicyclo (3,2,2)nonane derivatives, preparation and therapeutical use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014515754A (ja) * 2011-04-20 2014-07-03 サントル ナスィオナル ド ラ ルシェルシュ スィアンティフィク（セ．エン．エル．エス．） １，４−二置換１，２，３−トリアゾール、その調製方法、ならびにその診断的および治療的使用

Also Published As

Publication number Publication date
AU2004291457A1 (en) 2005-06-02
KR20060100426A (ko) 2006-09-20
CA2546096A1 (en) 2005-06-02
EP1687303A1 (en) 2006-08-09
SE0303075D0 (sv) 2003-11-19
US20070105896A1 (en) 2007-05-10
ZA200604018B (en) 2007-11-28
BRPI0416629A (pt) 2007-01-16
US7384954B2 (en) 2008-06-10
NO20062862L (no) 2006-08-21
IL175438A0 (en) 2006-09-05
WO2005049612A1 (en) 2005-06-02
CN1882584A (zh) 2006-12-20

Similar Documents

Publication Publication Date Title
RU2233282C2 (ru) Аралкиламины фуропиридинов, способ их получения, фармацевтическая композиция на их основе и промежуточные вещества
AU784400B2 (en) New use and novel N-azabicyclo-amide derivatives
US6706878B2 (en) Spiroazabicyclic heterocyclic compounds
RU2148058C1 (ru) Спиро-азабициклические соединения, способы их получения и промежуточные продукты
US20060052368A1 (en) Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists
AU2005233492B2 (en) Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor
JP2007515479A (ja) ニコチン性アセチルコリンレセプターリガンド
JP2007511603A (ja) ４−置換イミダゾール類
JP2007511602A (ja) ５−置換イミダゾール類
CN100445285C (zh) 烟碱性乙酰胆碱受体配体
JP2007515481A (ja) ニコチン性アセチルコリンレセプターリガンド
JP2007515478A (ja) ニコチン性アセチルコリンレセプターリガンド
MXPA06005416A (en) 4-substituted imidazoles
MXPA06005415A (en) 5-substituted imidazoles
EP1673372A1 (en) Non-amide nonanes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110823